An antioxidant drug, silibinin, modulates steroid secretion in human pathological adrenocortical cells

in Journal of Endocrinology
Authors:
K. Rácz
Search for other papers by K. Rácz in
Current site
Google Scholar
PubMed
Close
,
J. Fehér
Search for other papers by J. Fehér in
Current site
Google Scholar
PubMed
Close
,
G. Csomós
Search for other papers by G. Csomós in
Current site
Google Scholar
PubMed
Close
,
I. Varga
Search for other papers by I. Varga in
Current site
Google Scholar
PubMed
Close
,
R. Kiss
Search for other papers by R. Kiss in
Current site
Google Scholar
PubMed
Close
, and
E. Gláz
Search for other papers by E. Gláz in
Current site
Google Scholar
PubMed
Close
Restricted access
Rent on DeepDyve

Sign up for journal news

ABSTRACT

Because human adrenocortical cells from different adrenal disorders exhibit pathologically altered corticosteroid synthesis, and free radical mechanisms may induce pathological changes in the activities of corticosteroid biosynthetic enzymes (cytochrome P-450), we examined the effect of an antioxidant, silibinin, on basal and ACTH-stimulated secretion of several corticosteroids in isolated adrenal cells from an aldosterone-producing adenoma, atrophied adrenal tissues surrounding the adenoma, and hyperplastic adrenals from Cushing's syndrome. In the presence of a high concentration (100 μmol/l) of silibinin, variably diminished secretion of basal aldosterone, corticosterone, cortisol, 18-OH-corticosterone and 11-deoxycorticosterone was found. In contrast, the addition of 0·01 μmol silibinin/l, which failed to produce a clear effect on basal corticosteroid secretion, resulted in a potentiation of ACTH-stimulated secretion of several corticosteroids in the adenomatous and hyperplastic adrenocortical cells. These results suggest that the dose-dependent dual effect of silibinin on corticosteroid secretion may be attributed to corresponding changes in the activities of cytochrome P-450 enzymes, and that stimulation of ACTH-induced corticosteroidogenesis by silibinin is presumably due to the antioxidant property of the drug.

Journal of Endocrinology (1990) 124, 341–345

 

  • Collapse
  • Expand